Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Nature communications·2026

Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026

Same author

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Cell reports·2026

Same author

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i>-Mutant Melanoma.

bioRxiv : the preprint server for biology·2026

Same author

Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistance.

bioRxiv : the preprint server for biology·2026

Same author

A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.

Cell reports. Medicine·2026

Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026

Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026

Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026

Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026

Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026

Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 12, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

Targeting metastatic melanoma.

Keith T Flaherty¹

¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA. kflaherty@partners.org

Annual Review of Medicine

|November 1, 2011

Summary

This summary is machine-generated.

Metastatic melanoma, a difficult-to-treat cancer, is seeing breakthroughs due to understanding its genetics. BRAF-targeted therapies offer a new approach, with research exploring combination treatments for better outcomes.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Experiment Videos

Last Updated: May 12, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Area of Science:

Oncology
Genetics
Pharmacology

Background:

Metastatic melanoma is historically resistant to treatment.
Advances in understanding melanoma genetics have identified key oncogenic events.
Targeting these specific genetic alterations offers new therapeutic avenues.

Purpose of the Study:

To highlight the significance of genetic understanding in treating metastatic melanoma.
To introduce BRAF-targeted therapies as a major advancement.
To emphasize ongoing research in combination treatment strategies.

Main Methods:

Review of recent genetic discoveries in melanoma.
Analysis of the impact of BRAF-targeted therapies.
Discussion of translational research for combination therapies.

Main Results:

BRAF-targeted therapies represent a significant breakthrough in systemic melanoma treatment.
Genetic knowledge is crucial for developing effective targeted therapies.
Combination strategies are being investigated to enhance treatment efficacy.

Conclusions:

Targeted therapies based on genetic insights have revolutionized melanoma treatment.
Further research into combination therapies holds promise for improving outcomes in metastatic melanoma.
Understanding the genetic landscape is key to overcoming treatment resistance.